Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIRAL KANTILAL RABARA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1669788170
CMS profile
166938
Location
ROCK HILL, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$6,101.60

212 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Genmab U.S., Inc. $1,501.24 5
Novartis Pharmaceuticals Corporation $425.44 18
CTI BioPharma Corp. $338.59 12
Incyte Corporation $260.12 11
TAIHO ONCOLOGY, INC. $232.84 14
Merck Sharp & Dohme LLC $210.40 9
Janssen Biotech, Inc. $192.72 7
PFIZER INC. $182.07 12
Lilly USA, LLC $166.23 8
Genentech USA, Inc. $160.39 10
Takeda Pharmaceuticals U.S.A., Inc. $160.31 3
Alexion Pharmaceuticals, Inc. $150.95 3
Celgene Corporation $149.10 8
Stemline Therapeutics Inc. $128.09 4
GENZYME CORPORATION $113.26 2
AstraZeneca Pharmaceuticals LP $103.75 5
GlaxoSmithKline, LLC. $102.21 5
BeiGene USA, Inc. $100.35 3
Daiichi Sankyo Inc. $98.97 4
ARRAY BIOPHARMA INC $98.22 7
Amgen Inc. $97.61 5
E.R. Squibb & Sons, L.L.C. $89.05 6
Adaptive Biotechnologies Corporation $84.94 4
Seagen Inc. $78.29 4
Pharmacyclics LLC, An AbbVie Company $78.21 4
G1 Therapeutics, Inc. $68.63 3
Exelixis Inc. $57.74 3
Kyowa Kirin, Inc. $52.22 3
Karyopharm Therapeutics Inc. $50.32 2
Acrotech Biopharma Inc. $44.08 2
Kite Pharma, Inc. $42.31 3
EMD Serono, Inc. $40.46 2
Astellas Pharma US Inc $36.75 2
Regeneron Healthcare Solutions, Inc. $35.30 1
Gilead Sciences, Inc. $31.25 2
Foundation Medicine, Inc. $29.59 1
ABBVIE INC. $29.58 2
Celltrion USA Inc. $29.45 1
Novocure Inc. $27.50 1
PharmaEssentia USA Corporation $26.21 1
Deciphera Pharmaceuticals Inc. $25.92 1
Mirati Therapeutics, Inc. $25.57 1
Bayer Healthcare Pharmaceuticals Inc. $23.31 1
Boehringer Ingelheim Pharmaceuticals, Inc. $23.24 1
Eisai Inc. $22.60 1
Ipsen Biopharmaceuticals, Inc $18.45 1
Coherus Biosciences Inc. $17.07 1
AVEO Pharmaceuticals, Inc. $15.25 1
Pharmacosmos Therapeutics Inc. $14.98 1
Janssen Pharmaceuticals, Inc $10.47 1

Page 3 of 5; records 101–150 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIRAL KANTILAL RABARA

NPI 1669788170 · CMS profile ID 166938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ROCK HILL, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669788170?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIRAL KANTILAL RABARA, NPI 1669788170, CMS profile ID 166938. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669788170?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VIRAL KANTILAL RABARA, NPI 1669788170, CMS profile ID 166938. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669788170?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VIRAL KANTILAL RABARA, NPI 1669788170, CMS profile ID 166938, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 212 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1669788170?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

212 matching records · $6,101.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 212 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 212.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $18.6106/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032337829 CMS
Merck Sharp & Dohme LLC $31.8206/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048558639 CMS
Incyte Corporation $17.5406/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044539259 CMS
Kite Pharma, Inc. $16.6406/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025272779 CMS
Novartis Pharmaceuticals Corporation $25.4106/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992744647 CMS
Amgen Inc. $21.4906/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190335 CMS
Amgen Inc. $18.6006/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190331 CMS
Incyte Corporation $18.9906/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044539245 CMS
Novartis Pharmaceuticals Corporation $44.8106/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992744635 CMS
Coherus Biosciences Inc. $17.0706/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060237975 CMS
Genentech USA, Inc. $9.3906/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040592929 CMS
Genentech USA, Inc. $18.5006/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040592911 CMS
Exelixis Inc. $19.2706/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044566239 CMS
ARRAY BIOPHARMA INC $15.3206/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050633351 CMS
CTI BioPharma Corp. $19.5406/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039697517 CMS
Incyte Corporation $25.9606/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044539153 CMS
Merck Sharp & Dohme LLC $31.0905/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048823629 CMS
Genentech USA, Inc. $17.1005/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040592945 CMS
Kyowa Kirin, Inc. $22.4205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1027028375 CMS
TAIHO ONCOLOGY, INC. $20.4305/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055235537 CMS
Acrotech Biopharma Inc. $18.4505/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052993185 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.7605/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055551815 CMS
CTI BioPharma Corp. $9.1705/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039697513 CMS
Novartis Pharmaceuticals Corporation $34.9305/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992744639 CMS
Seagen Inc. $22.5705/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995810359 CMS
AVEO Pharmaceuticals, Inc. $15.2505/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049067271 CMS
Novartis Pharmaceuticals Corporation $25.9505/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992744631 CMS
PFIZER INC. $20.5605/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050357469 CMS
Janssen Biotech, Inc. $19.3005/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988523917 CMS
GENZYME CORPORATION $82.4805/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050177533 CMS
Karyopharm Therapeutics Inc. $21.7205/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056910491 CMS
Incyte Corporation $25.0005/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044539049 CMS
Pharmacyclics LLC, An AbbVie Company $21.4905/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998293359 CMS
Amgen Inc. $16.1105/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020190327 CMS
ARRAY BIOPHARMA INC $13.8705/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050388523 CMS
Genentech USA, Inc. $13.3105/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040592905 CMS
Mirati Therapeutics, Inc. $25.5705/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058000699 CMS
ABBVIE INC. $13.4305/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998179951 CMS
Genentech USA, Inc. $21.5705/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040592939 CMS
PFIZER INC. $20.4704/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050372933 CMS
TAIHO ONCOLOGY, INC. $20.5604/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055231623 CMS
Novartis Pharmaceuticals Corporation $27.1104/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992744627 CMS
EMD Serono, Inc. $21.8504/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032335311 CMS
BeiGene USA, Inc. $14.7004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189599 CMS
CTI BioPharma Corp. $152.2704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039697509 CMS
Lilly USA, LLC $26.6704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032606491 CMS
CTI BioPharma Corp. $20.8504/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039697505 CMS
Alexion Pharmaceuticals, Inc. $16.4904/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017053787 CMS
PharmaEssentia USA Corporation $26.2104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059301343 CMS
Novocure Inc. $27.5004/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021075391 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,708.72 162
PY2020 $1,576.97 87
PY2021 $4,253.83 153
PY2022 $4,543.62 203
PY2023 $6,101.60 212
PY2024 $12,122.73 191
PY2025 $7,301.99 183

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $8,220.00 4
PY2024 Principal investigator $48,589.84 11
PY2023 Principal investigator $30,168.10 10
PY2022 Principal investigator $10,381.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

4 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,150.00 05/15/2025 Non-covered Recipient Entity
CAROLINA BLOOD AND CANCER CARE ASSOCIATES PA
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737863
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $925.00 05/15/2025 Non-covered Recipient Entity
CAROLINA BLOOD AND CANCER CARE ASSOCIATES PA
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737865
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/15/2025 Non-covered Recipient Entity
CAROLINA BLOOD AND CANCER CARE ASSOCIATES PA
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737867
Principal investigator 1 AstraZeneca UK Limited $4,645.00 03/21/2025 Non-covered Recipient Entity
CAROLINA BLOOD AND CANCER CARE ASSOCIATES
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185553379